| ID | 10035 |
| Vaccine Name | Comirnaty |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | RNA based vaccine |
| Vaccine Status | Approved |
| Manufacturer | BioNTech SE, Pfizer Inc. |
| Year of Manufacturing | 2020 |
| Manufacturing Country | Germany |
| Age | 18 - 55 years |
| Dosage | 2 doses 21 days apart |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | Trimerized SARS-CoV-2 receptor-binding domain from spike protein |
| Description | mRNA based vaccine |
| Approving Organisation | US FDA |
| Collaborating Organisation | NA |
| Other Countries | Argentina, Brazil, Germany, South Africa, Turkey, USA |
| Trade Name | BNT162b2, COVID-19 mRNA vaccine |
| PMID | 33402220 |
| Clinical Trial ID | NA |
| Reference Link | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7785400/ |
| Additional Links | NA
|